Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

BRAINSTORM CELL THERAPEUTICS INC. Exhibit
EX-99.1 2 v471186_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS     HACKENSACK,…
To view the full exhibit click here

About Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.